Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Non-Current Assets for 10 years, with the latest figure at $231.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 5.06% year-over-year to $231.1 million; the trailing twelve-month figure through Mar 2026 stood at $945.2 million (down 3.31% YoY), and the FY2025 full-year result was $236.5 million, down 4.94% from the prior year.
• Non-Current Assets for Q1 2026 stood at $231.1 million, down from $236.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $250.0 million in Q4 2023, with the low at $30.6 million in Q2 2022.
• Historically, Non-Current Assets has averaged $211.5 million across 5 years, with a median of $236.8 million in 2025.
• Annual changes were most pronounced in 2022 — Non-Current Assets retreated 10.93% — and 2023, when it soared 677.77%.
• Kiniksa Pharmaceuticals International's Non-Current Assets stood at $216.6 million in 2022, then increased by 15.43% to $250.0 million in 2023, then retreated by 0.51% to $248.8 million in 2024, then retreated by 4.94% to $236.5 million in 2025, then slipped by 2.26% to $231.1 million in 2026.
• The last three Non-Current Assets figures came in at $231.1 million (Q1 2026), $236.5 million (Q4 2025), and $236.8 million (Q3 2025), per Business Quant data.